Fiche société
Stanford University
Traitements, essais et publications liés.
Traitements30programmes
Essais24liés
Publications3liées
SourceDBlocale
Traitements
30| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Non applicable | À vérifier | United States | À vérifier |
| BumetanideThis study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets. Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease. Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| Cilostazol 100 mg TabletsThe goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months. To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it. Participants will: * Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. * Not know which one they are taking, and neither will the study team, which keeps the results fair. * Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding. | Accident vasculaire cérébral, Maladie coronarienne | Phase 3 | À vérifier | United States | À vérifier |
| Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure MonitorThe goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients. The main question\[s\] it aims to answer are: 1. Does providing a free home blood pressure cuff improve control of hypertension? 2. Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations? 3. Does improved control of home blood pressure decrease adverse patient outcomes? Participants will be asked to * Take their blood pressure at home and records the results * Participate in follow-up phone calls from investigators at at 3 and 6 months Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education | Hypertension | NA | À vérifier | United States | À vérifier |
| PAANS — Pharmacology of Aminophylline for Acute Kidney Injury in NeonatesAcute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI. | SEP | À vérifier | À vérifier | United States | À vérifier |
| rapcabtagene autoleucel (YTB323)This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort. | SEP | Phase 1 | À vérifier | Australia, France, Germany, Italy, Spain, Switzerland | À vérifier |
| Rituximab 375 mg/m2Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects. This study assesses autologous stem cell transplant (ASCT) supplemented with high-dose therapy increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas, as an alternative to the limitations of conventional therapy. Preliminary studies with rituximab in low grade lymphomas indicate a response rate of about 50% with very little toxicity. Rituximab is hypothesized to be a candidate for post-transplant therapy because the majority of malignant lymphomas express the CD20 antigen; rituximab has impressive independent anti-tumor activity; and the antibody has little toxicity outside of the acute administration. | SEP | Phase 2 | Thérapie cellulaire + Immunomodulation | United States | À vérifier |
| Vibrotactile StimulationThe purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions. | Migraine | Non applicable | Traitement symptomatique | United States | À vérifier |
| BumetanideThis study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets. Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease. Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure MonitorThe goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients. The main question\[s\] it aims to answer are: 1. Does providing a free home blood pressure cuff improve control of hypertension? 2. Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations? 3. Does improved control of home blood pressure decrease adverse patient outcomes? Participants will be asked to * Take their blood pressure at home and records the results * Participate in follow-up phone calls from investigators at at 3 and 6 months Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education | Hypertension | NA | À vérifier | United States | À vérifier |
| rapcabtagene autoleucel (YTB323)This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort. | SEP | Phase 1/2 | À vérifier | Australia, France, Germany, Italy, Spain, Switzerland | À vérifier |
| Vibrotactile StimulationThe purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions. | Migraine | Non applicable | Traitement symptomatique | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Non applicable | À vérifier | United States | À vérifier |
| PAANS — Pharmacology of Aminophylline for Acute Kidney Injury in NeonatesAcute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI. | SEP | À vérifier | À vérifier | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 4 | À vérifier | Egypt | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| rapcabtagene autoleucel (YTB323)This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort. | SEP | Phase 1/2 | Ralentissement de la progression | Australia, Canada, France, Germany, Italy, Spain, Switzerland | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1 | À vérifier | À vérifier | |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1/2 | À vérifier | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Non applicable | À vérifier | À vérifier | |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | À vérifier | À vérifier | United Kingdom | À vérifier |
| rapcabtagene autoleucel (YTB323)This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | À vérifier | |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1 | Traitement symptomatique | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 1 | À vérifier | Egypt | À vérifier |
| Rituximab 375 mg/m2Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects. This study assesses autologous stem cell transplant (ASCT) supplemented with high-dose therapy increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas, as an alternative to the limitations of conventional therapy. Preliminary studies with rituximab in low grade lymphomas indicate a response rate of about 50% with very little toxicity. Rituximab is hypothesized to be a candidate for post-transplant therapy because the majority of malignant lymphomas express the CD20 antigen; rituximab has impressive independent anti-tumor activity; and the antibody has little toxicity outside of the acute administration. | SEP | Phase 2 | Thérapie cellulaire + Immunomodulation | United States | À vérifier |
| Cilostazol 100 mg TabletsThe goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months. To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it. Participants will: * Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. * Not know which one they are taking, and neither will the study team, which keeps the results fair. * Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding. | Accident vasculaire cérébral | Phase 3 | À vérifier | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 2/3 | À vérifier | Thailand | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Non applicable | À vérifier | United States | À vérifier |
| AminophyllineThis safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide. | SEP | Phase 3 | À vérifier | United States | À vérifier |
Essais cliniques
24| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Aminophylline | SEP | Phase 3 | NCT03897335 | Preventing Acute Kidney Injury (AKI) in Pediatric Patients | UNKNOWN |
| Aminophylline | SEP | Non applicable | NCT01759862 | RTphylline — Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant | COMPLETED |
| Aminophylline | SEP | Phase 2/3 | NCT06196853 | Prevention of Cisplatin-induced Nephrotoxicity | NOT_YET_RECRUITING |
| Cilostazol 100 mg Tablets | Accident vasculaire cérébral | Phase 3 | NCT07174414 | Clarity — Cilostazol for Prevention of Recurrent Stroke Trial | NOT_YET_RECRUITING |
| Rituximab 375 mg/m2 | SEP | Phase 2 | NCT00225212 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | COMPLETED |
| ExAblate 2100 | Cancer | Non applicable | NCT04298242 | Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment | COMPLETED |
| Aminophylline | SEP | Phase 1 | NCT04151381 | The Effect of Preoperative Aminophylline | UNKNOWN |
| Aminophylline | SEP | Phase 1 | NCT01240824 | Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer | COMPLETED |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1 | NCT07443137 | CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | NOT_YET_RECRUITING |
| Aminophylline | SEP | À vérifier | NCT02270827 | SARAH — A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics | TERMINATED |
| Aminophylline | SEP | Non applicable | NCT01280071 | Adenosine Activity in Producing Venoarteriolar Reflexes | UNKNOWN |
| Aminophylline | SEP | Phase 1/2 | NCT01702025 | Rapid Acclimatization to Hypoxia at Altitude | COMPLETED |
| Aminophylline | SEP | Phase 1 | NCT02983422 | Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient | UNKNOWN |
| Vagus nerve stimulation | SEP | Non applicable | NCT07310381 | Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | NOT_YET_RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06675864 | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | ACTIVE_NOT_RECRUITING |
| Aminophylline | SEP | Phase 1 | NCT01530464 | GQ01 — The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers | COMPLETED |
| Aminophylline | SEP | Phase 4 | NCT05552404 | Postdural Puncture Headache Relief With Aminophylline and SPGB | COMPLETED |
| PAANS — Pharmacology of Aminophylline for Acute Kidney Injury in Neonates | SEP | À vérifier | NCT02276170 | PAANS — Pharmacology of Aminophylline for Acute Kidney Injury in Neonates | TERMINATED |
| Aminophylline | SEP | Non applicable | NCT01245595 | KIDPROAM — Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery | COMPLETED |
| Aminophylline | SEP | Phase 1 | NCT01587027 | Safety Evaluation of Aminophylline and Methazolamide | COMPLETED |
| Vibrotactile Stimulation | Migraine | Non applicable | NCT04069572 | Vibratory Stimulation for the Treatment of Chronic Pain | SUSPENDED |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06617793 | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor | Hypertension | NA | NCT05730465 | Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor | UNKNOWN |
| Bumetanide | Alzheimer | Phase 2 | NCT06052163 | BumxAD — Bumetanide in Patients With Alzheimer's Disease | RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor | A village health worker intervention to reduce cardiovascular disease risk in remote areas of armed conflict in Myanmar-results from a feasibility study in three villages. | Conflict and health | ||
| Bumetanide | The NKCC1 Antagonist Bumetanide, Administered After Prenatal Alcohol Exposure, Mitigates Ethanol-Induced Aberrance in Tangential Migration of GABAergic Interneurons in Mouse Medial Prefrontal Cortex. | Alcohol, clinical & experimental research | ||
| Bumetanide | Synthesis of new sulfoximines and sulfonimidamides derivatives as NKCC1 inhibitors. | Frontiers in chemistry |